Back to search

Article

Safety, Pharmacokinetics, and Preliminary Efficacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 Study

2021-02-13

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Talazoparib is a poly(ADP-ribose) polymerase enzyme inhibitor. This open-label, non-randomized, phase 1 study of talazoparib investigated the safety, pharmacokinetics, and preliminary antitumor activity in Japanese patients with locally advanced or metastatic solid tumors, regardless of mutations in DNA damage repair-related genes, who are resistant to/ineligibl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9cd88d3c-8e4a-5855-aefe-d51044ffae6a
DOI
10.21203/rs.3.rs-189395/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety, Pharmacokinetics, and Preliminary Efficacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 StudyDOI 10.21203/rs.3.rs-189395/v1
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic CancersSemantic proximity
Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity
Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.Semantic proximity
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.Semantic proximity
Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity
Real-world efficacy and safety of belzutifan in patients with metastatic renal cell carcinoma: a multicenter retrospective study in JapanSemantic proximity
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.Semantic proximity
Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological EvaluationSemantic proximity
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.Semantic proximity
A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerSemantic proximity
Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the USSemantic proximity
Select a neighboring publication to make it the new centre.